医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

ReproCELL Launches Cell Innovation Partners, L.P. with Shinsei Bank, Limited

2014年09月29日 PM09:30
このエントリーをはてなブックマークに追加


 

YOKOHAMA, Japan

ReproCELL (JASDAQ:4978) announced that it has commenced operation of “Cell Innovation Partners, L.P.” (hereafter “the Fund”) at the size of about USD 8.0 million, as of September 26, 2014

Studies in pluripotent cells, including iPS cells, and in regenerative medicine have recently been accelerating in universities and research institutions worldwide; the issue now is financing the funds for development to apply the outcomes from studies in regenerative medicine. The Fund aims to contribute to the early practical application of the next generation of drug discovery and health care businesses by providing growth funds to cellular and regenerative medicine bio-venture companies inside and outside of Japan.

The Fund has the three following characteristics:

1.   The Fund will invest primarily in venture companies which focus on the development of pluripotent cell, including iPS cells, and regenerative medicine technology. The growth potential of investment candidate bio-venture companies which are expected to move into their business phase in five to seven years will be evaluated by ReproCELL, a pioneer in the iPS cell business, based on its understanding of the industry, the business, and the technology.
2. Investments will actively be made in overseas cellular and regenerative medicine bio-venture companies in the US and the EU, in addition to Japanese bio-venture companies.
3. Various Support will be provided to the bio-venture companies which have been invested in order to contribute to their growth.

Through the Fund, ReproCELL provides growth funds to venture companies in the iPS cellular and regenerative medicine areas, and secures, develops and works with innovative technological seeds around the world, promoting commercialization of regenerative medicine and its strengthening of competitiveness.

Summary of the Fund

Name   :   Cell Innovation Partners, L.P.
Country : Cayman Islands
Founded : March 2014
Fund size : About USD 8.0 million
General Partner :

Cell Innovation Partners Limited (URL: http://www.cell-ip.com)

Limited

Partner

: ReproCELL Incorporated, Shinsei Bank, Limited,

SMBC Strategy Series 2 Investment Limited Liability Partnership

Period : 7 years
Investment target : iPS cell and regenerative medicine bio-venture companies inside and outside of Japan

CONTACT

ReproCELL, Inc.
Chikafumi Yokoyama, +81-45-475-3887
PhD
info_en@reprocell.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • ENHERTU® Demonstrated Clinically Meaningful and Durable Response in Patients with HER2 Positive Advanced Gastric Cancer in DESTINY-Gastric02 Phase 2 Trial
  • 武田的EXKIVITY™ (mobocertinib)成为美国FDA首次核准的专为EGFR外显子20插入+ NSCLC患者设计的口服治疗药物
  • Masimo上市单例患者使用的rainbow® SuperSensor™
  • バーパックス・ファーマシューティカルズが4000万ドルの普通株式の公募売り出しを実施
  • BeiGene Receives Positive CHMP Opinion for BRUKINSA® (Zanubrutinib) for the Treatment of Adults with Waldenström’s Macroglobulinemia